Journal articles
Weedon M, Jackson L, Harrison J, Ruth K, Tyrrell J, Hattersley A, Wright C (In Press). Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation. BMJ: British Medical Journal
Jackson L, Weedon MN, Green HD, Mallabar-Rimmer B, Harrison JW, Wood AR, Ruth KS, Tyrrell J, Wright CF (2023). Influence of family history on penetrance of hereditary cancers in a population setting. eClinicalMedicine, 64, 102159-102159.
Cotton S, McHugh MP, Dewar R, Haas JG, Templeton K, Consortium TCGU, Robson SC, Connor TR, Loman NJ, Golubchik T, et al (2023). Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes. Journal of Hospital Infection, 135, 28-36.
Mokbel K, Daniels R, Weedon MN, Jackson L (2022). A Comparative Safety Analysis of Medicines Based on the UK Pharmacovigilance and General Practice Prescribing Data in England.
In Vivo,
36(2), 780-800.
Abstract:
A Comparative Safety Analysis of Medicines Based on the UK Pharmacovigilance and General Practice Prescribing Data in England.
BACKGROUND/AIM: Adverse drug reactions (ADRs) represent a major concern leading to significant increases in both morbidity and mortality globally. Providing healthcare professionals (HCPs) and patients with real-world data on drug safety is imperative to facilitate informed decision-making. The study aimed to determine the feasibility of creating comparative safety charts for medicines by mapping ADR reporting onto prescribing data. MATERIALS AND METHODS: Data on serious and fatal ADR reports from the Yellow Card database was mapped onto general practice prescription data in England. The rate of serious and fatal ADR reports per million items prescribed was calculated for commonly-prescribed medicines. RESULTS: Quantitative comparative analyses for 137 medicines belonging to 26 therapeutic classes were conducted. Significant differences were observed within most therapeutic classes for the rate of serious and fatal ADR reports per prescribing unit. CONCLUSION: Despite the limitations of ADR reporting and prescribing databases, the study provides a proof-of-concept for the feasibility of mapping ADR reporting onto prescribing data to create comparative safety charts that could support evidence-based decision-making around formulary choices.
Abstract.
Author URL.
Kläser K, Molteni E, Graham M, Canas LS, Österdahl MF, Antonelli M, Chen L, Deng J, Murray B, Kerfoot E, et al (2022). COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study.
Scientific Reports,
12(1).
Abstract:
COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study
The Delta (B.1.617.2) variant was the predominant UK circulating SARS-CoV-2 strain between May and December 2021. How Delta infection compares with previous variants is unknown. This prospective observational cohort study assessed symptomatic adults participating in the app-based COVID Symptom Study who tested positive for SARS-CoV-2 from May 26 to July 1, 2021 (Delta overwhelmingly the predominant circulating UK variant), compared (1:1, age- and sex-matched) with individuals presenting from December 28, 2020 to May 6, 2021 (Alpha (B.1.1.7) the predominant variant). We assessed illness (symptoms, duration, presentation to hospital) during Alpha- and Delta-predominant timeframes; and transmission, reinfection, and vaccine effectiveness during the Delta-predominant period. 3581 individuals (aged 18 to 100 years) from each timeframe were assessed. The seven most frequent symptoms were common to both variants. Within the first 28 days of illness, some symptoms were more common with Delta versus Alpha infection (including fever, sore throat, and headache) and some vice versa (dyspnoea). Symptom burden in the first week was higher with Delta versus Alpha infection; however, the odds of any given symptom lasting ≥ 7 days was either lower or unchanged. Illness duration ≥ 28 days was lower with Delta versus Alpha infection, though unchanged in unvaccinated individuals. Hospitalisation for COVID-19 was unchanged. The Delta variant appeared more (1.49) transmissible than Alpha. Re-infections were low in all UK regions. Vaccination markedly reduced the risk of Delta infection (by 69-84%). We conclude that COVID-19 from Delta or Alpha infections is similar. The Delta variant is more transmissible than Alpha; however, current vaccines showed good efficacy against disease. This research framework can be useful for future comparisons with new emerging variants.
Abstract.
Nickbakhsh S, Hughes J, Christofidis N, Griffiths E, Shaaban S, Enright J, Smollett K, Nomikou K, Palmalux N, Tong L, et al (2022). Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning.
Scientific Reports,
12(1).
Abstract:
Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning
Whole genome sequencing of SARS-CoV-2 has occurred at an unprecedented scale, and can be exploited for characterising outbreak risks at the fine-scale needed to inform control strategies. One setting at continued risk of COVID-19 outbreaks are higher education institutions, associated with student movements at the start of term, close living conditions within residential halls, and high social contact rates. Here we analysed SARS-CoV-2 whole genome sequences in combination with epidemiological data to investigate a large cluster of student cases associated with University of Glasgow accommodation in autumn 2020, Scotland. We identified 519 student cases of SARS-CoV-2 infection associated with this large cluster through contact tracing data, with 30% sequencing coverage for further analysis. We estimated at least 11 independent introductions of SARS-CoV-2 into the student population, with four comprising the majority of detected cases and consistent with separate outbreaks. These four outbreaks were curtailed within a week following implementation of control measures. The impact of student infections on the local community was short-term despite an underlying increase in community infections. Our study highlights the need for context-specific information in the formation of public health policy for higher educational settings.
Abstract.
Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, et al (2022). Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway (Nature Microbiology, (2022), 7, 8, (1161-1179), 10.1038/s41564-022-01143-7).
Nature Microbiology,
7(10).
Abstract:
Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway (Nature Microbiology, (2022), 7, 8, (1161-1179), 10.1038/s41564-022-01143-7)
In the version of this article initially published, the author affiliation information was incomplete, neglecting to note that Brian J. Willett, Joe Grove, Oscar A. MacLean, Craig Wilkie, Giuditta De Lorenzo, Wilhelm Furnon, Diego Cantoni, Sam Scott, Nicola Logan and Shirin Ashraf contributed equally and that John Haughney, David L. Robertson, Massimo Palmarini, Surajit Ray and Emma C. Thomson jointly supervised the work, as now indicated in the HTML and PDF versions of the article.
Abstract.
Wilkinson SAJ, Sparks N, Kele B, Peacock TP, Robson SC, Connor TR, Loman NJ, Golubchik T, Martinez Nunez RT, Bonsall D, et al (2022). Recurrent SARS-CoV-2 mutations in immunodeficient patients.
Virus Evolution,
8(2).
Abstract:
Recurrent SARS-CoV-2 mutations in immunodeficient patients
Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in immunodeficient patients are an important source of variation for the virus but are understudied. Many case studies have been published which describe one or a small number of long-term infected individuals but no study has combined these sequences into a cohesive dataset. This work aims to rectify this and study the genomics of this patient group through a combination of literature searches as well as identifying new case series directly from the COVID-19 Genomics UK (COG-UK) dataset. The spike gene receptor-binding domain and N-terminal domain (NTD) were identified as mutation hotspots. Numerous mutations associated with variants of concern were observed to emerge recurrently. Additionally a mutation in the envelope gene, T30I was determined to be the second most frequent recurrently occurring mutation arising in persistent infections. A high proportion of recurrent mutations in immunodeficient individuals are associated with ACE2 affinity, immune escape, or viral packaging optimisation.There is an apparent selective pressure for mutations that aid cell–cell transmission within the host or persistence which are often different from mutations that aid inter-host transmission, although the fact that multiple recurrent de novo mutations are considered defining for variants of concern strongly indicates that this potential source of novel variants should not be discounted.
Abstract.
Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, et al (2022). SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.
Nature Microbiology,
7(8), 1161-1179.
Abstract:
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the fifth VOC to be described, harbours multiple amino acid mutations in spike, half of which lie within the receptor-binding domain. Here we demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273. These data were mirrored by a substantial reduction in real-world vaccine effectiveness that was partially restored by booster vaccination. The Omicron variants BA.1 and BA.2 did not induce cell syncytia in vitro and favoured a TMPRSS2-independent endosomal entry pathway, these phenotypes mapping to distinct regions of the spike protein. Impaired cell fusion was determined by the receptor-binding domain, while endosomal entry mapped to the S2 domain. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant.
Abstract.
Eales O, Page AJ, de Oliveira Martins L, Wang H, Bodinier B, Haw D, Jonnerby J, Atchison C, Robson SC, Connor TR, et al (2022). SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2.
BMC Infectious Diseases,
22(1).
Abstract:
SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2
Background: Since the emergence of SARS-CoV-2, evolutionary pressure has driven large increases in the transmissibility of the virus. However, with increasing levels of immunity through vaccination and natural infection the evolutionary pressure will switch towards immune escape. Genomic surveillance in regions of high immunity is crucial in detecting emerging variants that can more successfully navigate the immune landscape. Methods: We present phylogenetic relationships and lineage dynamics within England (a country with high levels of immunity), as inferred from a random community sample of individuals who provided a self-administered throat and nose swab for rt-PCR testing as part of the REal-time Assessment of Community Transmission-1 (REACT-1) study. During round 14 (9 September–27 September 2021) and 15 (19 October–5 November 2021) lineages were determined for 1322 positive individuals, with 27.1% of those which reported their symptom status reporting no symptoms in the previous month. Results: We identified 44 unique lineages, all of which were Delta or Delta sub-lineages, and found a reduction in their mutation rate over the study period. The proportion of the Delta sub-lineage AY.4.2 was increasing, with a reproduction number 15% (95% CI 8–23%) greater than the most prevalent lineage, AY.4. Further, AY.4.2 was less associated with the most predictive COVID-19 symptoms (p = 0.029) and had a reduced mutation rate (p = 0.050). Both AY.4.2 and AY.4 were found to be geographically clustered in September but this was no longer the case by late October/early November, with only the lineage AY.6 exhibiting clustering towards the South of England. Conclusions: As SARS-CoV-2 moves towards endemicity and new variants emerge, genomic data obtained from random community samples can augment routine surveillance data without the potential biases introduced due to higher sampling rates of symptomatic individuals.
Abstract.
Goodman S, Skirton H, Jackson L, Jones RB (2021). Development of a secure website to facilitate information sharing in families at high risk of bowel cancer— the familyweb study.
Cancers,
13(10).
Abstract:
Development of a secure website to facilitate information sharing in families at high risk of bowel cancer— the familyweb study
Individuals with pathogenic variants in genes predisposing to bowel cancer are encour-aged to share this information within their families. Close relatives at 50% risk can have access to bowel cancer surveillance. However, many relatives remain unaware of their vulnerability or have insufficient information. We investigated the feasibility and acceptability of using a secure website to support information sharing within families at high risk of bowel cancer. Patients (n = 286) answered an anonymous cross-sectional survey, with 14 participating in telephone interviews. They reported that the diagnosis had a profound effect on them and their family relationships, and consequently desired more support from health professionals. Website content was created in response to the preferences of survey and interview participants. Reactions to the website from 12 volunteers were captured through remote usability testing to guide further refinement of the website. Participants welcomed the opportunity to store and share personal information via the website and wanted more information and help informing their relatives about the diagnosis. Important website topics were: healthy lifestyle; genetic testing; and how to talk to children about the diagnosis. A website providing online access to confidential documents was both feasible and acceptable and could translate into increased uptake of cancer surveillance, resulting in lower morbidity and mortality in these families.
Abstract.
Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Page AJ, et al (2021). Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant.
Science,
374(6574).
Abstract:
Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were rising during early summer 2021 in many countries as a result of the Delta variant. We assessed reverse transcription polymerase chain reaction swab positivity in the Real-time Assessment of Community Transmission–1 (REACT-1) study in England. During June and July 2021, we observed sustained exponential growth with an average doubling time of 25 days, driven by complete replacement of the Alpha variant by Delta and by high prevalence at younger, less-vaccinated ages. Prevalence among unvaccinated people [1.21% (95% credible interval 1.03%, 1.41%)] was three times that among double-vaccinated people [0.40% (95% credible interval 0.34%, 0.48%)]. However, after adjusting for age and other variables, vaccine effectiveness for double-vaccinated people was estimated at between ~50% and ~60% during this period in England. Increased social mixing in the presence of Delta had the potential to generate sustained growth in infections, even at high levels of vaccination.
Abstract.
Author URL.
Godino L, Turchetti D, Jackson L, Hennessy C, Skirton H (2021). Genetic counselling as a route to enhanced autonomy: using a sequential mixed methods research approach to develop a theory regarding presymptomatic genetic testing for young adults at risk of inherited cancer syndromes. Journal of Community Genetics, 12(4), 685-691.
Vöhringer HS, Sanderson T, Sinnott M, De Maio N, Nguyen T, Goater R, Schwach F, Harrison I, Hellewell J, Ariani CV, et al (2021). Genomic reconstruction of the SARS-CoV-2 epidemic in England.
Nature,
600(7889), 506-511.
Abstract:
Genomic reconstruction of the SARS-CoV-2 epidemic in England
AbstractThe evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus leads to new variants that warrant timely epidemiological characterization. Here we use the dense genomic surveillance data generated by the COVID-19 Genomics UK Consortium to reconstruct the dynamics of 71 different lineages in each of 315 English local authorities between September 2020 and June 2021. This analysis reveals a series of subepidemics that peaked in early autumn 2020, followed by a jump in transmissibility of the B.1.1.7/Alpha lineage. The Alpha variant grew when other lineages declined during the second national lockdown and regionally tiered restrictions between November and December 2020. A third more stringent national lockdown suppressed the Alpha variant and eliminated nearly all other lineages in early 2021. Yet a series of variants (most of which contained the spike E484K mutation) defied these trends and persisted at moderately increasing proportions. However, by accounting for sustained introductions, we found that the transmissibility of these variants is unlikely to have exceeded the transmissibility of the Alpha variant. Finally, B.1.617.2/Delta was repeatedly introduced in England and grew rapidly in early summer 2021, constituting approximately 98% of sampled SARS-CoV-2 genomes on 26 June 2021.
Abstract.
de Silva TI, Liu G, Lindsey BB, Dong D, Moore SC, Hsu NS, Shah D, Wellington D, Mentzer AJ, Angyal A, et al (2021). The impact of viral mutations on recognition by SARS-CoV-2 specific T cells.
iScience,
24(11).
Abstract:
The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
We identify amino acid variants within dominant SARS-CoV-2 T cell epitopes by interrogating global sequence data. Several variants within nucleocapsid and ORF3a epitopes have arisen independently in multiple lineages and result in loss of recognition by epitope-specific T cells assessed by IFN-γ and cytotoxic killing assays. Complete loss of T cell responsiveness was seen due to Q213K in the A∗01:01-restricted CD8+ ORF3a epitope FTSDYYQLY207-215; due to P13L, P13S, and P13T in the B∗27:05-restricted CD8+ nucleocapsid epitope QRNAPRITF9-17; and due to T362I and P365S in the A∗03:01/A∗11:01-restricted CD8+ nucleocapsid epitope KTFPPTEPK361-369. CD8+ T cell lines unable to recognize variant epitopes have diverse T cell receptor repertoires. These data demonstrate the potential for T cell evasion and highlight the need for ongoing surveillance for variants capable of escaping T cell as well as humoral immunity.
Abstract.
Turner H, Jackson L (2020). Evidence for penetrance in patients without a family history of disease: a systematic review.
EUROPEAN JOURNAL OF HUMAN GENETICS,
28(5), 539-550.
Author URL.
Godino L, Turchetti D, Jackson L, Hennessy C, Skirton H (2019). Presymptomatic genetic testing for hereditary cancer in young adults: a survey of young adults and parents. European Journal of Human Genetics, 27(2).
Carrieri D, Howard HC, Benjamin C, Clarke AJ, Dheensa S, Doheny S, Hawkins N, Halbersma-Konings TF, Jackson L, Kayserili H, et al (2019). Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics. European Journal of Human Genetics, 27(2).
Jackson L, O'Connor A, Paneque M, Curtisova V, Lunt PW, Pourova RK, Macek MJ, Stefansdottir V, Turchetti D, Campos M, et al (2019). The Gen-Equip Project: evaluation and impact of genetics e-learning resources for primary care in six European languages (vol 21, pg 718, 2018).
GENETICS IN MEDICINE,
21(7), 1669-1669.
Author URL.
Vears DF, Senecal K, Clarke AJ, Jackson L, Laberge AM, Lovrecic L, Piton A, Van Gassen KLI, Yntema HG, Knoppers BM, et al (2018). <i>Points to consider</i> for laboratories reporting results from diagnostic genomic sequencing.
EUROPEAN JOURNAL OF HUMAN GENETICS,
26(1), 36-43.
Author URL.
Godino L, Jackson L, Turchetti D, Hennessy C, Skirton H (2018). Decision making and experiences of young adults undergoing presymptomatic genetic testing for familial cancer: a longitudinal grounded theory study. European Journal of Human Genetics, 26(1).
Carrieri D, Jackson L, Bewshea C, Prainsack B, Mansfield J, Ahmad T, Hawkins N, Kelly S (2018). Ethical issues in genomic research: Proposing guiding principles co-produced with stakeholders. Clinical Ethics, 13(4), 194-198.
Jackson L, O’Connor A, Paneque M, Curtisova V, Lunt PW, Pourova RK, Macek M, Stefansdottir V, Turchetti D, Campos M, et al (2018). The Gen-Equip Project: evaluation and impact of genetics e-learning resources for primary care in six European languages. Genetics in Medicine, 1-1.
Borry P, Bentzen HB, Budin-Ljøsne I, Cornel MC, Howard HC, Feeney O, Jackson L, Mascalzoni D, Mendes Á, Peterlin B, et al (2018). The challenges of the expanded availability of genomic information: an agenda-setting paper. Journal of community genetics, 9(2), 103-116.
Wassall R, Jackson L, Prasad S, Homfray T, Skirton H (2017). Health care for young adults undergoing predictive genetic testing for cardiomyopathies. British Journal of Cardiac Nursing, 12(8), 378-386.
Paneque M, Cornel MC, Curtisova V, Houwink E, Jackson L, Kent A, Lunt P, Macek M, Stefansdottir V, Turchetti D, et al (2017). Implementing genetic education in primary care: the Gen-Equip programme. Journal of community genetics, 8(2), 147-150.
Paneque M, Turchetti D, Jackson L, Lunt P, Houwink E, Skirton H (2016). A systematic review of interventions to provide genetics education for primary care. BMC family practice, 17(1).
Pisnoli L, O’Connor A, Goldsmith L, Jackson L, Skirton H (2016). Impact of fetal or child loss on parents’ perceptions of non-invasive prenatal diagnosis for autosomal recessive conditions. Midwifery, 34, 105-110.
Hennessy C, Jackson L, Turchetti D, Godino L, Skirton H (2016). Impact of presymptomatic genetic testing on young adults: a systematic review.
Godino L, Turchetti D, Jackson L, Hennessy C, Skirton H (2016). Impact of presymptomatic genetic testing on young adults: a systematic review. European Journal of Human Genetics, 24(4).
Skirton H, Jackson L (2015). Factors Affecting the Clinical Use of Non-Invasive Prenatal Testing.
Jackson L, O'Connor A, Goldsmith L, Skirton H (2015). Management of Incidental Findings from Genetic Tests: Perspectives of Ethics Committee Members. Journal of Clinical Research & Bioethics, 6(3).
Skirton H, Goldsmith L, Jackson L, Lewis C, Chitty LS (2015). Non‐invasive prenatal testing for aneuploidy: a systematic review of Internet advertising to potential users by commercial companies and private health providers. Prenatal diagnosis, 35(12), 1167-1175.
O'connor A, Jackson L, Goldsmith L, Skirton H (2014). Can I get a retweet please? Health research recruitment and the Twittersphere. Journal of advanced nursing, 70(3), 599-609.
Skirton H, Goldsmith L, Jackson L, Lewis C, Chitty L (2014). Erratum: Offering prenatal diagnostic tests: European guidelines for clinical practice. European Journal of Human Genetics, 22(5), 714-714.
Jackson L, Goldsmith L, Skirton H (2014). Guidance for patients considering direct-to-consumer genetic testing and health professionals involved in their care: development of a practical decision tool. Family practice, 31(3), 341-348.
Skirton H, Goldsmith L, Jackson L, Lewis C, Chitty L (2014). Offering prenatal diagnostic tests: European guidelines for clinical practice. European Journal of Human Genetics, 22(5).
Patel SK, Jackson L, Warren AY, Arya P, Shaw RW, Khan RN (2013). A role for two‐pore potassium (K2P) channels in endometrial epithelial function. Journal of cellular and molecular medicine, 17(1), 134-146.
Skirton H, Jackson L, Goldsmith L, O’Connor A (2013). Are health professionals ready for direct-to-consumer genetic and genomic testing?. Personalized medicine, 10(7), 673-682.
Skirton H, Goldsmith L, Jackson L, O'Connor LA (2013). Direct to Consumer Genetic Testing: a Systematic Review of Position Statements, Policies and Recommendations (vol 68, pg 16, 2013).
OBSTETRICAL & GYNECOLOGICAL SURVEY,
68(2), 160-162.
Author URL.
Goldsmith L, Jackson L, O’Connor A, Skirton H (2013). Direct-to-consumer genomic testing from the perspective of the health professional: a systematic review of the literature. Journal of community genetics, 4(2), 169-180.
Skirton H, Goldsmith L, Jackson L, O'Connor LA (2013). Erratum: Direct to consumer genetic testing: a systematic review of position statements, policies and recommendations (Obstetrical and Gynecological Survey (2013) 68:1 (16-18)). Obstetrical and Gynecological Survey, 68(2), 160-162.
Innamaa A, Jackson L, Asher V, Van Schalkwyk G, Warren A, Keightley A, Hay D, Bali A, Sowter H, Khan R, et al (2013). Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer. Clinical and Translational Oncology, 15(11), 910-918.
Innamaa A, Jackson L, Asher V, Van Shalkwyk G, Warren A, Hay D, Bali A, Sowter H, Khan R (2013). Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma. Anticancer research, 33(4), 1401-1408.
Goldsmith L, Woodward V, Jackson L, Skirton H (2013). Informed consent for blood tests in people with a learning disability. Journal of advanced nursing, 69(9), 1966-1976.
Skirton H, Goldsmith L, Jackson L, O'Connor LA (2013). Perinatal outcome in women treated with progesterone for the prevention of preterm birth: a meta-analysis: Editorial comment. Obstetrical and Gynecological Survey, 68(1), 20-22.
Skirton H, Goldsmith L, Jackson L, Tibben A (2013). Quality in genetic counselling for presymptomatic testing—clinical guidelines for practice across the range of genetic conditions. European Journal of Human Genetics, 21(3).
Skirton H, Jackson L (2013). Utility and limitations of genetic/genomic information and testing. Nursing Standard (through 2013), 28(13).
Innamaa A, Jackson L, Asher V, van Shalkwyk G, Warren A, Hay D, Bali A, Sowter H, Khan R (2013). expression and function of the two pore potassium (k2p) channels Trek-1 (kcnk2), Trek-2 (kcnk10) and Task-3 (kcnk9) in ovarian cancer. Bjog: an International Journal of Obstetrics and Gynaecology, 120(9), e5-e6.
Rashidi H, Strohbuecker S, Jackson L, Kalra S, Blake AJ, France L, Tufarelli C, Sottile V (2012). Differences in the pattern and regulation of mineral deposition in human cell lines of osteogenic and non-osteogenic origin. Cells Tissues Organs, 195(6), 484-494.
Skirton H, Goldsmith L, Jackson L, O'Connor A (2012). Direct to consumer genetic testing: a systematic review of position statements, policies and recommendations. Clinical genetics, 82(3), 210-218.
Goldsmith L, Jackson L, O'connor A, Skirton H (2012). Direct-to-consumer genomic testing: systematic review of the literature on user perspectives. European Journal of Human Genetics, 20(8).
Skirton H, Jackson L, Goldsmith L, O’Connor A (2012). Genomic medicine: what are the challenges for the National Health Service?. Personalized medicine, 9(5), 539-545.
Jackson L, Goldsmith L, O'connor A, Skirton H (2012). Incidental findings in genetic research and clinical diagnostic tests: a systematic review. American Journal of Medical Genetics Part A, 158(12), 3159-3167.
Jackson L, Jones DR, Scotting P, Sottile V (2007). Adult mesenchymal stem cells: differentiation potential and therapeutic applications. Journal of postgraduate medicine, 53(2).
Jackson L (2001). Incidental Findings in Genetic Research and Genetic Testing. eLS